LACTOLOGY FOUNDATION

Hexocyclium (ATC A03AB10) is a synthetic quaternary antimuscarinic used historically for functional gastrointestinal disorders; it is now largely discontinued and data for lactation are very limited, so only cautious, exceptional use in breastfeeding can be justified, with preference for better‑studied alternatives.medpedia.framar+5

Pharmacological profile

Hexocyclium is classified by WHO ATC as A03AB10 within “synthetic anticholinergics, quaternary ammonium compounds” for functional GI disorders.drugbank+1
It is a muscarinic acetylcholine receptor antagonist, typically used as the methyl sulfate salt (hexocyclium methylsulfate) for clinical administration.wikipedia+3
As a quaternary ammonium compound, systemic absorption from the gut is relatively limited compared with tertiary amines, and penetration into the central nervous system is poor.pubchem.ncbi.nlm.nih+1

Mechanism of action
Hexocyclium binds competitively to muscarinic receptors (predominantly M3) in the gastrointestinal tract, inhibiting acetylcholine‑mediated smooth muscle contraction and secretory activity.sciencedirect+2
This results in reduced gastrointestinal motility and decreased gastric acid secretion, providing symptomatic relief in functional GI disorders, peptic ulcer disease, and diarrhea.drugbank+2
Its pharmacodynamic profile is broadly similar to other antimuscarinic antispasmodics (e.g. propantheline, dicycloverine), but with quaternary structure limiting CNS penetration.sps+2

Clinical indications and current status
Hexocyclium was formerly marketed under trade names such as Tral for the treatment of peptic ulcers and functional GI disturbances.sciencedirect+1
DrugBank and other databases note that these products have been discontinued and hexocyclium is no longer widely available in contemporary practice.pubchem.ncbi.nlm.nih+1
In modern guidelines on GI antispasmodics in breastfeeding, hexocyclium is generally not discussed, reflecting its obsolete status and very limited clinical use.sciencedirect+1

Toxicological considerations

General adverse effects
Like other muscarinic antagonists, hexocyclium can produce the typical anticholinergic spectrum: dry mouth, blurred vision, tachycardia, constipation, urinary retention and, less commonly, confusion or agitation.drugbank+2
Quaternary structure reduces CNS effects, but peripheral anticholinergic toxicity remains relevant, especially at higher doses or in susceptible populations (elderly, cardiac disease, prostate hypertrophy).sciencedirect+1
The Bulgarian source lists hypersensitivity to the drug or excipients as a formal contraindication and emphasizes physician consultation before use.medpedia.framar

Overdose and toxicity
Overdose may intensify anticholinergic manifestations: severe tachycardia, hyperthermia, marked urinary retention, paralytic ileus and pronounced visual disturbances.pubchem.ncbi.nlm.nih+2
Because of poor CNS penetration, central toxicity (delirium, hallucinations, seizures) is less prominent than with tertiary agents such as atropine or scopolamine, but cannot be excluded, particularly in infants or in compromised blood–brain barrier states.sciencedirect
Management of significant toxicity follows general antimuscarinic overdose principles: supportive care, treatment of hyperthermia, cardiac monitoring, and, in selected cases, cautious use of physostigmine under specialist supervision.sciencedirect

Drug interactions and special risk groups
Hexocyclium may exacerbate adverse effects when combined with other anticholinergic agents (e.g. tricyclic antidepressants, antihistamines, antipsychotics) due to additive muscarinic blockade.drugbank+1
Concomitant use with drugs that slow GI motility (opioids, loperamide) increases risk of severe constipation or ileus, particularly in postoperative or elderly patients.drugbank+1
Patients with glaucoma, urinary outflow obstruction, severe ulcerative colitis or myasthenia gravis are at increased risk of serious complications and are generally considered unsuitable candidates for antimuscarinic therapy.sciencedirect

Use during pregnancy and lactation

General lactation principles
Most medicines pass into breast milk in amounts below 10% of the maternal dose and are often compatible with breastfeeding, but antimuscarinics are potentially problematic because of pharmacological effects on both infant and milk production.medsafe+1
Guidance on GI antispasmodics during breastfeeding recommends better‑characterized agents such as hyoscine butylbromide, propantheline or peppermint oil as preferred choices, with dicycloverine explicitly discouraged due to reported infant apnoea.sps

Hexocyclium: lactation data and theoretical assessment
There is no specific published quantitative data on hexocyclium concentrations in human milk or documented series of exposed infants, and major lactation reference sites (MotherToBaby, InfantRisk) do not list dedicated monographs for this obsolete drug.infantrisk+1
ScienceDirect’s overview of hexocyclium and related antimuscarinics notes that in breastfeeding, infants should be monitored for adverse effects, and use should be at the lowest effective dose with avoidance of dosing at breastfeeding times, reflecting a cautious, generalized stance.sciencedirect+1
Given its quaternary structure, oral bioavailability in the infant is likely limited, but theoretical risk exists for reduced GI motility, feeding difficulties, and anticholinergic symptoms (dry mouth, irritability, poor weight gain), especially in neonates or premature infants.medsafe+2

Impact on milk production
Antimuscarinic drugs such as atropine and propantheline have been associated with suppression of breast milk production in theoretical and limited clinical observations, and similar effects may be extrapolated for hexocyclium.sps+1
Therefore, in breastfeeding women, any antimuscarinic GI antispasmodic should be used with caution, with careful monitoring of infant feeding and maternal milk supply, and preference given to short‑acting agents with more robust safety data.medsafe+1

Risk–benefit evaluation in breastfeeding
In a breastfeeding mother with functional GI disorder, the potential benefits of hexocyclium must be weighed against uncertain infant exposure and the availability of better‑studied alternatives.sciencedirect+2
If use is unavoidable (e.g. legacy product, lack of alternatives), dosing should be minimized, treatment duration kept short, and breastfeeding scheduled to occur just before maternal dosing to reduce infant exposure during peak plasma levels.medsafe+2
Infant monitoring should focus on signs of anticholinergic toxicity (poor sucking, decreased wet diapers, constipation, unusual drowsiness or irritability) and on weight gain, with prompt discontinuation and medical review if concerns arise.sps+2

Illustrative clinical scenario
For example, a mother with severe functional diarrhea unresponsive to other agents might receive a short course of hexocyclium under specialist supervision, but contemporary guidance would favor switching to a preferred antispasmodic with known lactation safety whenever possible.sciencedirect+1

Practical recommendations for healthcare professionals

Prescribing stance
Hexocyclium belongs to an outdated class of GI antispasmodics and is largely discontinued; many modern formularies no longer list it as an available product.pgx-db+3
In non‑lactating adults, use should still follow antimuscarinic precautions (contraindications, interaction screening, titration to lowest effective dose) and be individualized according to comorbidities.drugbank+1

Breastfeeding mothers
For breastfeeding patients with functional GI complaints, preferred options include hyoscine butylbromide, propantheline, mebeverine, alverine, or non‑pharmacologic strategies, which have more supporting data for lactation safety.medsafe+1
Hexocyclium should generally be avoided in breastfeeding due to lack of evidence and potential for anticholinergic effects on the infant and lactation; if absolutely necessary, a risk‑minimization strategy and close clinical follow‑up are essential.sps+2

Information and counseling
Clinicians should explain to breastfeeding mothers that most medicines are compatible with breastfeeding but that older antimuscarinic agents such as hexocyclium carry theoretical risks and lack modern safety data.sciencedirect+2
Mothers should be encouraged to report any infant symptoms promptly and to consult specialist lactation resources or teratology information services when considering GI antispasmodics.mothertobaby+2